Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.

December 12, 2018

Phase 2 Myeloma Trial for Investigational CAR T-cell Therapy bb2121 Completes Enrollment

News

An international Phase 2 trial testing the investigational CAR T-cell therapy bb2121 for the treatment of relapsed or refractory multiple myeloma patients has completed patient recruitment, Celgene and bluebird bio announced. The KarMMa ... Read more

November 14, 2018

FDA Clears Way for Trials of FOR46 in Late-stage Multiple Myeloma, Prostate Cancer

News

The U.S. Food and Drug Administration has allowed Fortis Therapeutics’ antibody-drug conjugate FOR46 to begin testing in a Phase 1 clinical trial as a therapy for late-stage multiple myeloma. ... Read more

November 12, 2018

FDA Approves Empliciti Combination for Relapsed or Refractory Multiple Myeloma

News

The U.S. Food and Drug Administration has approved Bristol-Myers Squibb‘s Empliciti (elotuzumab), in combination with Pomalyst (pomalidomide) and low-dose dexamethasone, as a treatment for patients with relapsed or treatment-resistant multiple myeloma. The ... Read more

November 5, 2018

Myeloma Crowd Launches Online Tool to Help Patients Find Treatment Options, Contribute to Research

News

Myeloma Crowd has launched an online tool called HealthTree, aimed at helping patients with multiple myeloma find the most appropriate therapies for their condition, while boosting research toward a potential cure ... Read more

August 30, 2018August 30, 2018

Amgen Seeks Expanded Approval of Kyprolis to Once-weekly Regimen for Relapsed Myeloma

News

Amgen is seeking to expand the approval of its proteasome inhibitor Kyprolis (carfilzomib) in the U.S. to include once-weekly dosing combined with dexamethasone for multiple myeloma patients with hard-to-treat disease or ... Read more

August 27, 2018August 27, 2018

FDA Grants Priority Review to Empliciti Combo Therapy for Relapsed or Refractory Myeloma

News

The U.S. Food and Drug Administration granted priority review to Bristol-Myers Squibb’s supplemental Biologics License Application (sBLA) for Empliciti (elotuzumab) combined with Pomalyst (pomalidomide) and low-dose dexamethasone as a treatment for patients with relapsed or treatment-resistant multiple ... Read more

August 6, 2018

Investigational Immunotherapy SRF231 Granted FDA Orphan Drug Status for Multiple Myeloma

News

The U.S. Food and Drug Administration has granted orphan drug status to SRF231 to treat multiple myeloma, according to Surface Oncology, which is developing the investigational therapy. Orphan drug designation aims ... Read more

August 3, 2018

CHMP Recommends Darzalex Combo Therapy for Certain Newly Diagnosed Multiple Myeloma Patients

News

Expanded use of Darzalex (daratumumab) in combination with standard therapy for treating adult patients with newly-diagnosed multiple myeloma, and who are not candidates for stem cell transplant, has been recommended by ... Read more

July 18, 2018

Ninlaro Maintenance Therapy Fares Well in Phase 3 Multiple Myeloma Trial

News

Takeda‘s proteasome inhibitor Ninlaro (ixazomib) prevents multiple myeloma from progressing or returning when given as a maintenance therapy to patients who responded to first-line therapy and stem cell transplant, a Phase ... Read more

June 29, 2018

Empliciti Triple Combo Delays Disease Progression in Advanced Myeloma Patients, Phase 2 Trial Data Show

News

Adding Empliciti (elotuzumab) to a combination of Pomalyst (pomalidomide) and dexamethasone significantly delays disease worsening or death in myeloma patients who failed to respond to previous treatment, data from the Phase 2 ELOQUENT-3 trial ... Read more